Rate Setting

How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs

New state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]

Read More
  • State Health Policy Blog

    How States Could Lower Costs for Brand Name Drugs

    States are searching for new and innovative approaches to handle the rising cost of prescription medicines – both the sudden spike in spending that comes with a new high-cost treatment and the ongoing challenges of regular, inexplicable, price hikes for all covered drugs. The United States has the highest prescription drug prices in the world. […]

    Read More
  • Publications
    States and the Rising Cost of Pharmaceuticals: A Call to Action

    States and the Rising Cost of Pharmaceuticals: A Call to Action

    As part of the 29th Annual State Health Policy Conference, held 17-19 in Pittsburgh, PA, NASHP released findings from our Pharmacy Costs Work Group aimed at addressing the increasingly rising costs of pharmaceuticals.  The solutions offered in the newly released findings serve as a toolbox for states. While they recognize the value of the pharmaceutical industry, state policymakers […]

    Read More
  • Publications

    States and Prescription Drugs: An Overview of State Programs to Rein in Costs

    States are significant purchasers of health care for Medicaid, inmates in correctional facilities, and public employees. Despite considerable efforts to maintain affordability, drug pricing continues to vex state budgets. While Medicaid is the largest single health expenditure in state budgets, spending on health care for public workers including state employees and retirees, legislators, judicial employees, […]

    Read More